RxSight Re-elects Directors at Annual Meeting

An announcement from RxSight ( (RXST) ) is now available.

RxSight held its 2025 Annual Meeting of Stockholders on June 3, 2025, where approximately 79.2% of the outstanding shares were represented. During the meeting, three Class I directors, Ron Kurtz, M.D., J. Andy Corley, and Juliet Tammenoms Bakker, were re-elected to serve until the 2028 annual meeting. Additionally, the stockholders approved the executive compensation and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (RXST) stock is a Buy with a $73.00 price target. To see the full list of analyst forecasts on RxSight stock, see the RXST Stock Forecast page.

Spark’s Take on RXST Stock

According to Spark, TipRanks’ AI Analyst, RXST is a Neutral.

RxSight’s stock score of 43 reflects strong revenue growth and a solid balance sheet, countered by significant profitability and cash flow challenges. The technical indicators suggest a bearish trend with oversold conditions, while a negative P/E ratio and lack of dividend yield weigh on its valuation. The recent earnings call highlighted both positive customer sentiment and growth, but revised guidance and market challenges pose risks to future performance.

To see Spark’s full report on RXST stock, click here.

More about RxSight

Average Trading Volume: 1,033,875

Technical Sentiment Signal: Sell

Current Market Cap: $631.1M

For detailed information about RXST stock, go to TipRanks’ Stock Analysis page.